221. KRASG12D Cells Override Homeostatic Cell Elimination Mechanisms in Adult Pancreas Via Wnt5a and Cell Dormancy.
作者: Beatriz Salvador-Barbero.;Markella Alatsatianos.;Jennifer P Morton.;Owen J Sansom.;Catherine Hogan.
来源: Gastroenterology. 2025年
The adult pancreas protects against cancer by actively expelling genetically mutated cells. Pancreatic cancer starts with cells carrying KRAS mutations; however, it is not clear how some KRAS mutant cells override cell elimination mechanisms to survive in tissues.
222. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials.
作者: Behrad Saeedian.;Nastaran Babajani.;Tannaz Bagheri.;Fatemeh Ojaghi Shirmard.;Seyed Morteza Pourfaraji.
来源: BMC Gastroenterol. 2025年25卷1期230页
Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease. Some patients with PBC do not adequately respond to Ursodeoxycholic acid (UDCA) as a first-line treatment, putting them at an increased risk of disease progression. Peroxisome Proliferator-Activated Receptor (PPAR) agonists are emerging as promising therapeutic options for PBC. We aim to investigate the efficacy and safety of PPAR agonists in treating PBC patients.
223. High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease.
作者: Hao Wang.;Junzhao Ye.;Youpeng Chen.;Yanhong Sun.;Xiaorong Gong.;Hong Deng.;Zhiyong Dong.;Lishu Xu.;Xin Li.;Bihui Zhong.
来源: BMC Gastroenterol. 2025年25卷1期231页
Whether include high-sensitivity C-reactive protein (Hs-CRP) in diagnostic flow remains debatable during the updated definition to metabolic dysfunction-associated steatotic liver disease (MASLD) despite systemic inflammation contributes to the disease development and progression. We aimed to identify values of hs-CRP compared to other inflammatory markers derived from routine blood tests in MASLD.
224. Risk factors for enteral feeding intolerance in critically ill patients: an updated systematic review and meta-analysis.
This meta-analysis aimed to evaluate the factors influencing enteral nutrition feeding intolerance in critically ill patients.
225. Burden of gastrointestinal cancers in Asia, 1990-2019.
Gastrointestinal (GI) cancers are a major cause of morbidity and mortality worldwide. However, there has been no comprehensive assessment of GI cancers in Asia.
226. Association between fibrosis-4 index (FIB-4) and gallstones: an analysis of the NHANES 2017-2020 cross-sectional study.
作者: Huqiang Dong.;Zufa Zhang.;Chang Fu.;Mixue Guo.;Haifeng Zhang.;Xintian Cai.;Hongping Cheng.
来源: BMC Gastroenterol. 2025年25卷1期229页
Gallstones are a common digestive disorder, yet the association between the fibrosis-4 index (FIB-4) and gallstone formation remains poorly understood. This study explores the link between FIB-4 levels and gallstone prevalence among US adults.
227. Iceball growth 3D simulation model based on finite element method for hepatic cryoablation planning.
作者: Shengwei Li.;Yumeng Zhang.;Fanyu Zhou.;Sheng Xu.;Yufeng Wang.;Lin Cheng.;Zhixin Bie.;Bin Li.;Xiao-Guang Li.
来源: BMC Gastroenterol. 2025年25卷1期227页
Cryoablation simulation based on Finite Element Method (FEM) can facilitate preoperative planning for liver tumors. However, it has limited application in clinical practice due to its time-consuming process and improvable accuracy. We aimed to propose a FEM-based simulation model for rapid and accurate prediction of the iceball size during the hepatic cryofreezing cycle.
228. Triglyceride-glucose index and triglyceride-to-high-density lipoprotein cholesterol ratio in predicting severity of acute pancreatitis: a cross-sectional clinical study.
The aim of this study is to investigate the correlation of triglyceride-glucose (TyG) index and triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio with acute pancreatitis (AP), and to compare the predictive value of the two indexes for severe AP (SAP).
229. Long transparent cap-assisted clip closure technique: a new choice for gastrointestinal defect closure.
作者: Nan Dai.;Changqing Guo.;Shanshan Zhu.;Saif Ullah.;Jingwen Zhang.;Ping Liu.;Fangbin Zhang.;Xinguang Cao.
来源: BMC Gastroenterol. 2025年25卷1期228页
To evaluate the safety and effectiveness of the novel long transparent cap-assisted clip closure technique in closing gastrointestinal defects.
230. The impact of refined nursing management on the diagnosis of early gastric cancer under ME-NBI.
To explore the impact of magnifying endoscopy with narrow-band imaging (ME-NBI) combined with refined nursing management on the endoscopic diagnosis of early gastric cancer.
231. The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis.
作者: Taimoor Ashraf.;Omar Abunada.;Nandlal Seerani.;Kashif Ali.;Areej Muhammad.;Syeda Lamiya Mir.;Syed Adil Mir Shah.;Muhammad Hassaan.;Vikash Kumar.;Waseem Abbas.;Simran Bajaj.;Asfia Qammar.;F N U Deepak.;Salih Abdella Yusuf.
来源: BMC Gastroenterol. 2025年25卷1期224页
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct destruction, leading to cholestasis and, if untreated, liver failure. Although ursodeoxycholic acid (UDCA) remains the first-line treatment, many patients exhibit an inadequate response, necessitating alternative therapeutic options. Seladelpar, a peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, has emerged as a promising alternative due to its anti-inflammatory and anti-fibrotic properties.
233. Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma.
作者: Guanzhi Ye.;Gaojian Pan.;Xiaolei Zhu.;Hongming Liu.;Ning Li.;Guojun Geng.;Jie Jiang.
来源: BMC Gastroenterol. 2025年25卷1期223页
The optimal time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery for esophageal squamous cell carcinoma remains unknown. This research aims to assess the impact of time interval on pathological response and survival prognosis.
234. The role of Triglyceride Glucose-Waist Circumference (TyG_WC) in predicting metabolic dysfunction-associated steatotic liver disease among individuals with hyperuricemia.
作者: Qian-Qian Wang.;Ning Zhang.;Xiang Xu.;Si-Ang Lv.;Zhuo-Deng Huang.;Xi-Dai Long.;Jun Wu.
来源: BMC Gastroenterol. 2025年25卷1期220页
The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) among individuals with hyperuricemia is significantly high. The aim of this study was to identify effective biomarkers for the detection of MASLD among patients with hyperuricemia.
235. Optimization of electrode position in electric field treatment for pancreatic cancer.
作者: Sangcheol Kim.;Yousun Ko.;Dongho Shin.;Haksoo Kim.;Sung Uk Lee.;Jonghyun Kim.;Tae Hyun Kim.;Myonggeun Yoon.
来源: BMC Gastroenterol. 2025年25卷1期222页
In electric field-based cancer treatment, the intensity of the electric field applied to the tumor depends on the position of the electrode array, directly affecting the efficacy of treatment. The present study evaluated the effects of changing the position of the electrode array on the efficacy of electric field treatment for pancreatic cancer.
236. The double-edged sword: impact of antibiotic use on immunotherapy efficacy in advanced hepatocellular carcinoma.
作者: Yang Li.;Ziwei Feng.;Canhua Liang.;Shaohuan Lu.;GuangZhao Wang.;Guangyi Meng.
来源: BMC Gastroenterol. 2025年25卷1期221页
This retrospective study aims to evaluate the impact of antibiotics (ATBs) use on the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC), providing insights into the prudent use of ATBs in patients undergoing immunotherapy.
237. A randomized open label pilot study evaluating the efficacy of two dosing regimens of rifamycin SV MMX in the treatment of small intestinal bacterial overgrowth.
作者: Bradley A Connor.;Marina Rogova.;Jefferson Garcia.;Morgan Gardner.;Charandeep Waraich.;Victoria Averill.
来源: BMC Gastroenterol. 2025年25卷1期219页
Antibiotics have demonstrated efficacy in the eradication of the underlying overgrowth bacteria and improvement of symptoms of small intestinal bacterial overgrowth (SIBO). The use of standard antibiotics may cause intolerable side effects such as development of multidrug-resistant enteric bacteria, Clostridioides difficile infections and dysbiosis. Nonabsorbable antibiotics have the advantage of minimized side effects. Rifaximin, an antibiotic of the ansamycin class has been shown to be effective in the treatment of SIBO. We evaluated the use of another ansamycin antibiotic, rifamycin SV MMX (AEMCOLO) in the treatment of SIBO. One difference from rifaximin is the site of delivery of AEMCOLO which appears to be the distal small intestine and colon. Hence by maintaining the microbial milieu of the proximal small intestine, the clearance of the overgrowth bacteria might be enhanced. The side effect profile of Rifamycin SV MMX has been described elsewhere in the pivotal trials; there were no safety signals noted in this study. This randomized open label pilot study evaluated the efficacy of two dosing regimens of AEMCOLO in treating SIBO. We used a simple randomization method to assign participants into study groups. The participants included 31 patients, split between two treatment arms: one receiving the medication twice daily and the other - three times daily. The outcomes were assessed based on symptom improvement and breath test normalization. The results indicated a beneficial response with both dosing regimens leading to symptom improvement and breath test normalization. Further evaluation revealed that in the three-time daily regimen, greater symptomatic improvement was observed. For clinicians treating SIBO, this study suggests that AEMCOLO is a viable treatment option. A double-blind, placebo-controlled design will probably be necessary to ascertain the true efficacy of different dosing regimens of AEMCOLO in treating SIBO.
238. Cardiometabolic index as a predictor of gallstone risk: evidence from NHANES 2017-2020.
作者: Huachao Zheng.;Bo Wu.;Caixiang Zhuang.;Jiesheng Mao.;Min Li.;Yuncheng Luo.;Lidong Huang.;Sisi Lin.;Feiyang Zhao.;Yiren Hu.
来源: BMC Gastroenterol. 2025年25卷1期218页
The Cardiometabolic Index (CMI), a composite marker integrating lipid profiles (triglycerides-to-HDL-C ratio) and abdominal obesity (waist-to-height ratio), we aimed to assess its association with gallstone prevalence.
239. Association between wet-bulb globe temperature with peptic ulcer disease in different geographic regions in a large Taiwanese population study.
作者: Yuh-Ching Gau.;Chia-Yu Kuo.;Wei-Yu Su.;Wan-Ling Tsai.;Ying-Jhen Wu.;Ping-Hsun Wu.;Ming-Yen Lin.;Chih-Da Wu.;Chao-Hung Kuo.;Szu-Chia Chen.
来源: BMC Gastroenterol. 2025年25卷1期216页
Peptic ulcer disease (PUD) is a common and important cause of morbidity worldwide, with a large impact on healthcare costs. Little research has been conducted on the association between wet-bulb globe temperature (WBGT) and PUD. The aim of this study was to explore this association among different geographical regions of Taiwan in a large sample of participants.
240. The prevalence of Barrett 's esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis.
作者: Maryam Rashidian.;Fatemeh Bastan.;Hedieh Soltani.;Reza Ghosheni.;Kiyarash Bakhshande.;Mahdi Mohammaditabar.;Yasin Tabatabaei Mehr.;Khaled Rahmani.;Mahmood Bakhtiyari.;Mostafa Qorbani.;Mojgan Forootan.;Mahsa Mohammadi.;Mohsen Rajabnia.
来源: BMC Gastroenterol. 2025年25卷1期217页
Barrett's esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant.
|